Assenagon Asset Management S.A. Buys Shares of 5,224 ICU Medical, Inc. $ICUI

Assenagon Asset Management S.A. acquired a new stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 5,224 shares of the medical instruments supplier’s stock, valued at approximately $745,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SJS Investment Consulting Inc. lifted its holdings in shares of ICU Medical by 41,000.0% in the third quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 410 shares during the period. Covestor Ltd grew its holdings in ICU Medical by 70.7% during the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 236 shares during the period. Smartleaf Asset Management LLC raised its position in ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after acquiring an additional 101 shares in the last quarter. Headlands Technologies LLC bought a new stake in ICU Medical in the second quarter worth about $177,000. Finally, United Services Automobile Association acquired a new stake in ICU Medical in the 1st quarter valued at about $218,000. Institutional investors own 96.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. KeyCorp lifted their price target on shares of ICU Medical from $175.00 to $180.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research note on Thursday, January 22nd. Piper Sandler boosted their price objective on ICU Medical from $172.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Finally, Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday, February 15th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $179.33.

ICU Medical Trading Down 3.0%

Shares of NASDAQ:ICUI opened at $125.22 on Thursday. The company has a current ratio of 2.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $3.13 billion, a PE ratio of 6,264.13, a P/E/G ratio of 1.86 and a beta of 0.85. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $160.29. The firm has a fifty day moving average price of $141.65 and a 200 day moving average price of $137.94.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.23. The company had revenue of $535.94 million during the quarter, compared to analysts’ expectations of $541.20 million. ICU Medical had a return on equity of 7.33% and a net margin of 0.03%.The business’s quarterly revenue was down 14.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.11 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.